Wave Life Sciences, Inc. (WVE) stock
WVENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 10/3046% below fair value
$2.84−0.03 (-1.05%)
Close on Nov 17, 2026Market cap $560.13MP/E –Yield –
Wave Life Sciences price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Wave Life Sciences's price to sales ratio was 10.1× on Nov 11, 2026, against 6.7× a year earlier. Over the last 5 years it ranged from 2.0× to 145.6×, with a median of 15.2×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 10.1× | −5.1 |
| 2024 | Oct 31, 2024 | 15.2× | +9.3 |
| 2023 | Dec 29, 2023 | 5.8× | −139.8 |
| 2022 | Dec 30, 2022 | 145.6× | +130.7 |
| 2021 | Apr 30, 2021 | 14.9× | −14.5 |
| 2020 | Dec 31, 2020 | 29.4× | +13.5 |
| 2019 | Dec 31, 2019 | 16.0× | −88.1 |
| 2018 | Dec 31, 2018 | 104.0× | −176.8 |
| 2017 | Dec 29, 2017 | 280.8× | – |
See a number that looks wrong?